IRLAB to present clinical and preclinical data at the AD/PD™ 2026 – 20th International Conference on Alzheimer’s & Parkinson’s Diseases

Gothenburg, Sweden, March 17, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that it will showcase three abstracts at the AD/PDTM 2026 – 20th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, taking place in Copenhagen, Denmark, March 17-21, 2026.

IRLAB participates in Life Science Day in Gothenburg on March 4, 2026

IRLAB secures milestone payment for first patient dosed in Phase Ib study with IRL757 in Parkinson’s Disease